Hepatitis C Drugmaker
- All
- News
-
Cadila Seeks Nod To Repurpose Hepatitis C Drug For Covid Treatment
Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
Novartis judgement: What it means for you
The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.
-
Cadila Seeks Nod To Repurpose Hepatitis C Drug For Covid Treatment
Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
Novartis judgement: What it means for you
The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.
